NovelStem International Corp. (NSTM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.2 Million USD | 1090.42% |
| 2022 | 353.32 Thousand USD | 82.88% |
| 2021 | 193.2 Thousand USD | 181.04% |
| 2020 | 68.74 Thousand USD | 0.0% |
| 2013 | 1.39 Million USD | -15.71% |
| 2012 | 1.65 Million USD | -54.61% |
| 2011 | 3.64 Million USD | -61.87% |
| 2010 | 9.56 Million USD | -61.91% |
| 2009 | 25.11 Million USD | -14.06% |
| 2008 | 29.22 Million USD | -23.85% |
| 2007 | 38.37 Million USD | -13.27% |
| 2006 | 44.24 Million USD | 8.41% |
| 2005 | 40.81 Million USD | 80.69% |
| 2004 | 22.58 Million USD | 0.07% |
| 2003 | 22.57 Million USD | 8.65% |
| 2002 | 20.77 Million USD | 28.26% |
| 2001 | 16.19 Million USD | 55.4% |
| 2000 | 10.42 Million USD | -17.92% |
| 1999 | 12.7 Million USD | 86.76% |
| 1998 | 6.8 Million USD | -8.11% |
| 1997 | 7.4 Million USD | 85.0% |
| 1996 | 4 Million USD | 8.11% |
| 1995 | 3.7 Million USD | 42.31% |
| 1994 | 2.6 Million USD | 1200.0% |
| 1993 | 200 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.87 Million USD | 4.99% |
| 2024 Q1 | 4.64 Million USD | 10.37% |
| 2023 Q1 | 523.7 Thousand USD | 48.22% |
| 2023 FY | 4.2 Million USD | 1090.42% |
| 2023 Q4 | 4.2 Million USD | 4.28% |
| 2023 Q3 | 4.03 Million USD | 32.77% |
| 2023 Q2 | 3.03 Million USD | 480.1% |
| 2022 Q3 | 293.84 Thousand USD | 45.43% |
| 2022 Q4 | 353.32 Thousand USD | 20.24% |
| 2022 FY | 353.32 Thousand USD | 82.88% |
| 2022 Q1 | 69.9 Thousand USD | -63.82% |
| 2022 Q2 | 202.05 Thousand USD | 189.06% |
| 2021 Q1 | - USD | 0.0% |
| 2021 FY | 193.2 Thousand USD | 181.04% |
| 2021 Q4 | 193.2 Thousand USD | 0.0% |
| 2020 FY | 68.74 Thousand USD | 0.0% |
| 2013 Q3 | 1.63 Million USD | -5.85% |
| 2013 FY | 1.39 Million USD | -15.71% |
| 2013 Q1 | 1.51 Million USD | -8.27% |
| 2013 Q2 | 1.73 Million USD | 14.28% |
| 2013 Q4 | 1.39 Million USD | -14.59% |
| 2012 Q2 | 2.69 Million USD | -22.49% |
| 2012 Q3 | 1.58 Million USD | -41.4% |
| 2012 Q4 | 1.65 Million USD | 4.75% |
| 2012 FY | 1.65 Million USD | -54.61% |
| 2012 Q1 | 3.47 Million USD | -4.61% |
| 2011 Q3 | 4.41 Million USD | -12.57% |
| 2011 FY | 3.64 Million USD | -61.87% |
| 2011 Q1 | 5.17 Million USD | -45.88% |
| 2011 Q4 | 3.64 Million USD | -17.42% |
| 2011 Q2 | 5.05 Million USD | -2.42% |
| 2010 Q2 | 21.05 Million USD | -26.74% |
| 2010 Q4 | 9.56 Million USD | -57.44% |
| 2010 Q3 | 22.47 Million USD | 6.75% |
| 2010 Q1 | 28.74 Million USD | 14.43% |
| 2010 FY | 9.56 Million USD | -61.91% |
| 2009 Q4 | 25.11 Million USD | 13.97% |
| 2009 Q1 | 29.62 Million USD | 1.36% |
| 2009 FY | 25.11 Million USD | -14.06% |
| 2009 Q2 | 21.12 Million USD | -28.69% |
| 2009 Q3 | 22.03 Million USD | 4.34% |
| 2008 Q1 | 40.08 Million USD | 4.45% |
| 2008 FY | 29.22 Million USD | -23.85% |
| 2008 Q3 | 30.88 Million USD | -1.56% |
| 2008 Q2 | 31.37 Million USD | -21.73% |
| 2008 Q4 | 29.22 Million USD | -5.38% |
| 2007 Q1 | 49.33 Million USD | 11.49% |
| 2007 FY | 38.37 Million USD | -13.27% |
| 2007 Q4 | 38.37 Million USD | -2.4% |
| 2007 Q3 | 39.32 Million USD | 7.69% |
| 2007 Q2 | 36.51 Million USD | -25.99% |
| 2006 Q2 | 43.1 Million USD | -10.55% |
| 2006 Q4 | 44.24 Million USD | 2.9% |
| 2006 FY | 44.24 Million USD | 8.41% |
| 2006 Q3 | 43 Million USD | -0.24% |
| 2006 Q1 | 48.18 Million USD | 18.07% |
| 2005 Q4 | 40.81 Million USD | 47.06% |
| 2005 Q3 | 27.75 Million USD | 6.75% |
| 2005 Q2 | 25.99 Million USD | -5.1% |
| 2005 Q1 | 27.39 Million USD | 21.28% |
| 2005 FY | 40.81 Million USD | 80.69% |
| 2004 Q4 | 22.58 Million USD | 33.2% |
| 2004 FY | 22.58 Million USD | 0.07% |
| 2004 Q1 | 22.35 Million USD | -0.96% |
| 2004 Q2 | 18.83 Million USD | -15.76% |
| 2004 Q3 | 16.95 Million USD | -9.95% |
| 2003 Q2 | 21.97 Million USD | -1.03% |
| 2003 Q1 | 22.2 Million USD | 6.88% |
| 2003 FY | 22.57 Million USD | 8.65% |
| 2003 Q3 | 22.86 Million USD | 4.03% |
| 2003 Q4 | 22.57 Million USD | -1.27% |
| 2002 FY | 20.77 Million USD | 28.26% |
| 2002 Q3 | 18.85 Million USD | -7.71% |
| 2002 Q4 | 20.77 Million USD | 10.2% |
| 2002 Q2 | 20.42 Million USD | -6.72% |
| 2002 Q1 | 21.89 Million USD | 35.19% |
| 2001 Q1 | 10.03 Million USD | -3.7% |
| 2001 FY | 16.19 Million USD | 55.4% |
| 2001 Q2 | 16.21 Million USD | 61.49% |
| 2001 Q4 | 16.19 Million USD | 8.04% |
| 2001 Q3 | 14.99 Million USD | -7.52% |
| 2000 Q3 | 13.23 Million USD | 46.79% |
| 2000 Q4 | 10.42 Million USD | -21.25% |
| 2000 Q2 | 9.01 Million USD | 21.06% |
| 2000 Q1 | 7.44 Million USD | -41.35% |
| 2000 FY | 10.42 Million USD | -17.92% |
| 1999 Q4 | 12.7 Million USD | 104.84% |
| 1999 Q3 | 6.2 Million USD | -11.43% |
| 1999 FY | 12.7 Million USD | 86.76% |
| 1999 Q1 | 5.1 Million USD | -25.0% |
| 1999 Q2 | 7 Million USD | 37.25% |
| 1998 Q2 | 7.3 Million USD | 2.82% |
| 1998 Q3 | 7.6 Million USD | 4.11% |
| 1998 Q4 | 6.8 Million USD | -10.53% |
| 1998 Q1 | 7.1 Million USD | -4.05% |
| 1998 FY | 6.8 Million USD | -8.11% |
| 1997 Q3 | 4.2 Million USD | -17.65% |
| 1997 FY | 7.4 Million USD | 85.0% |
| 1997 Q4 | 7.4 Million USD | 76.19% |
| 1997 Q1 | 4.2 Million USD | 5.0% |
| 1997 Q2 | 5.1 Million USD | 21.43% |
| 1996 Q4 | 4 Million USD | 11.11% |
| 1996 FY | 4 Million USD | 8.11% |
| 1996 Q1 | 5.5 Million USD | 48.65% |
| 1996 Q2 | 3.9 Million USD | -29.09% |
| 1996 Q3 | 3.6 Million USD | -7.69% |
| 1995 FY | 3.7 Million USD | 42.31% |
| 1995 Q3 | 2.5 Million USD | 0.0% |
| 1995 Q4 | 3.7 Million USD | 48.0% |
| 1994 Q4 | 2.6 Million USD | 136.36% |
| 1994 FY | 2.6 Million USD | 1200.0% |
| 1994 Q2 | 400 Thousand USD | 0.0% |
| 1994 Q3 | 1.1 Million USD | 175.0% |
| 1993 Q4 | 200 Thousand USD | 0.0% |
| 1993 FY | 200 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -16.576% |
| Arrayit Corporation | 7.49 Million USD | 43.893% |
| Atlantic International Corp. | 3.82 Million USD | -9.859% |
| Biocept, Inc. | 22.01 Million USD | 80.893% |
| Bioqual, Inc. | 18.93 Million USD | 77.79% |
| CardioGenics Holdings Inc | 1.79 Million USD | -134.332% |
| DermTech, Inc. | 64.75 Million USD | 93.505% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.428% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 66.042% |
| iMD Companies, Inc. | 1.67 Million USD | -151.227% |
| IDenta Corp. | 1.01 Million USD | -315.145% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 85.062% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -1311.687% |
| InVitro International | 78.99 Thousand USD | -5224.825% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 78.681% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -3153.037% |
| Medical Imaging Corp. | 9.51 Million USD | 55.805% |
| Optigenex Inc. | 9.57 Million USD | 56.052% |
| PharmChem, Inc. | 558.64 Thousand USD | -652.905% |
| Proteome Sciences plc | 18.48 Million USD | 77.251% |
| Response Genetics, Inc | 15.86 Million USD | 73.492% |
| Rennova Health, Inc. | 49.66 Million USD | 91.532% |
| RushNet, Inc. | 6.23 Million USD | 32.584% |
| ScreenPro Security Inc. | 1.6 Million USD | -162.784% |
| Stella Diagnostics Inc. | 18 Million USD | 76.64% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 48.731% |
| Todos Medical Ltd. | 50.15 Million USD | 91.614% |